Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPABID: Pipamperone and Aripiprazole for Behaviors that Challenge in Intellectual Disabilities
2024-519833-51-00Phase 4Authorised
- Sponsor
- GGZ Drenthe
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in intellectual disability (ID) and behavioral disorder comparing Pipamperone N-of-1 crossover with Aripiprazole N-of-1 crossover (2 arms). Planned start Jan 2026; status: authorised.
02
Drugs
pipamperonearipiprazole
03
Conditions
intellectual disability (ID)behavioral disorder
Beyond the preview
Go deeper on 2024-519833-51-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519833-51-00.